Business
Decision Diagnostics and Subsidiaries Elaborate on the Patent Infringement Lawsuit Against Johnson & Johnson and Two of Its Divisions
Decision Diagnostics and Subsidiaries Elaborate on the Patent Infringement Lawsuit Against Johnson & Johnson and Two of Its Divisions.
About this update from Decision Diagnostics Corp
[{"type":"text","content":"\n \n \n Decision Diagnostics and Subsidiaries Elaborate on the Patent Infringement Lawsuit Against Johnson & Johnson and Two of Its Divisions\n \n \nDecision Diagnostics and Subsidiaries Elaborate on the Patent Infringement Lawsuit Against Johnson & Johnson and Two of Its Divisions\n \n LOS ANGELES, CA--(Marketwired - Mar 16, 2016) - Decision Diagnostics Corp. (OTC PINK: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for GenStrip™ 50 and the GenUltimate™ glucose test strip, both designed to work with the market leading Johnson & Johnson's (\"J&J\") LifeScan OneTouch Ultra family of glucose testing meters, and the in-development GenSure™ glucose test strip targeted to the developing world markets, today announced that on March 14, 2016 its wholly owned subsidiaries, Decision IT Corp. and Pharma Tech Solutions, Inc., had filed a lawsuit in the United States District Court, District of Nevada, in Las Vegas, NV against Johnson & Johnson and its divisions Lifescan, Inc. and Lifescan Scotland Ltd. (hereafter: Lifescan) stipulating multiple incidences of infringement against two separate patents owned and/or practiced by the company's subsidiaries. The company is seeking compensation and damages in the amount of $400-$700 million. \n The central issues in our patent infringement case concern the following features:\n \n \n A test strip that features three electrodes with two operating through the utilization of the same reference electrode,\n \nA test strip and meter in which multiple readings are taken at each of the two working electrodes over a small period of time, making use of the Cottrell equation,\n \nThe test strip technology that compares the measurements between the two working electrodes to assure that each are within a fixed percentage\n \n \n These technological features have enabled and propelled the success of the Lifescan OneTouch Ultra blood glucose test system throughout the global diabetic test marketplace. They have achieved an annual windfall of $2 billion in gross revenues in each of the last six years. \n Each of those identified fundamental features above are covered by US Patents 6,153,069 and 6,413,411. Both of those patents are fully owned by the Decision Diagnostics subsi...